{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:45:19Z","timestamp":1786149919833,"version":"build-2736575974"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011606","name":"Mach-Gaensslen Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000884","name":"Cancer Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000001","name":"Alberta Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ygyno.2026.06.011","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T19:47:29Z","timestamp":1783972049000},"page":"148-152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The real-world utility of homologous repair deficiency testing in BRCA1\/2 wild-type high-grade serous carcinoma and the utility of MYC amplification as a potential surrogate marker"],"prefix":"10.1016","volume":"211","author":[{"given":"Radha","family":"Maradiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Kinloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"De Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"de Biase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soufian","family":"El Hallani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Tallini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"K\u00f6bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Han","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa","family":"Aubrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ygyno.2026.06.011_bb0005","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3390\/ijms20040952","article-title":"High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints","volume":"20","author":"Lisio","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.ygyno.2026.06.011_bb0010","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/gcc.22935","article-title":"Parp inhibitors in ovarian cancer: an overview of the practice-changing trials","volume":"60","author":"Foo","year":"2021","journal-title":"Genes Chromosomes Cancer"},{"issue":"26","key":"10.1016\/j.ygyno.2026.06.011_bb0015","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.ygyno.2026.06.011_bb0020","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.ygyno.2026.06.011_bb0025","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","article-title":"Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"35","author":"Monk","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2026.06.011_bb0030","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.2147\/OTT.S272199","article-title":"Ovarian cancer therapy: homologous recombination deficiency as a predictive biomarker of response to parp inhibitors","volume":"15","author":"Miller","year":"2022","journal-title":"Onco. Targets Ther."},{"issue":"15","key":"10.1016\/j.ygyno.2026.06.011_bb0035","doi-asserted-by":"crossref","first-page":"8125","DOI":"10.3390\/ijms23158125","article-title":"The molecular mechanisms of actions, effects, and clinical implications of parp inhibitors in epithelial ovarian cancers: a systematic review","volume":"23","author":"Lau","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.ygyno.2026.06.011_bb0040","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s11523-023-00970-w","article-title":"Parp inhibitors in ovarian cancer: a review","volume":"18","author":"O\u2019Malley","year":"2023","journal-title":"Target. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2026.06.011_bb0045","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.annonc.2020.08.2102","article-title":"ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer","volume":"31","author":"Miller","year":"2020","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2026.06.011_bb0050","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/COC.0000000000001010","article-title":"Real-world outcomes associated with poly(ADP-ribose) polymerase inhibitor monotherapy maintenance in patients with primary advanced ovarian cancer","volume":"46","author":"Chan","year":"2023","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.06.011_bb0055","series-title":"Topics in Biostatistics","first-page":"33","article-title":"Descriptive statistics","author":"Nick","year":"2007"},{"key":"10.1016\/j.ygyno.2026.06.011_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114127","article-title":"Harmonization of homologous recombination deficiency testing in ovarian cancer: results from the MITO16A\/MaNGO-OV2 trial","volume":"206","author":"Roma","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"20","key":"10.1016\/j.ygyno.2026.06.011_bb0065","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1158\/1078-0432.CCR-24-1225","article-title":"Effectiveness of parp inhibitor maintenance therapy in ovarian cancer by brca1\/2 and a scar-based hrd signature in real-world practice","volume":"30","author":"Richardson","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2026.06.011_bb0070","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ygyno.2024.11.011","article-title":"Association between genomic instability score and progression-free\/overall survival in patients with newly diagnosed non-BRCA1\/2 ovarian cancer","volume":"192","author":"Graves","year":"2025","journal-title":"Gynecol. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2026.06.011_bb0080","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41588-018-0179-8","article-title":"Copy number signatures and mutational processes in ovarian carcinoma","volume":"50","author":"Macintyre","year":"2018","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ygyno.2026.06.011_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.772604","article-title":"Inferring homologous recombination deficiency of ovarian cancer from the landscape of copy number variation at subchromosomal and genetic resolutions","volume":"11","author":"Zhang","year":"2021","journal-title":"Front. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826020317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826020317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:34:28Z","timestamp":1786149268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826020317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":16,"alternative-id":["S0090825826020317"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.06.011","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The real-world utility of homologous repair deficiency testing in BRCA1\/2 wild-type high-grade serous carcinoma and the utility of MYC amplification as a potential surrogate marker","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}